ライフサイエンスコーパス: external-beam radiotherapy

1 ue radiotherapy are comparable to those from external beam radiotherapy.

2 with the conventional policy of whole breast external beam radiotherapy.

3 tive radiotherapy and 1119 were allocated to external beam radiotherapy.

4 ed targeted intraoperative radiotherapy plus external beam radiotherapy.

5 ith quality indicators than those undergoing external beam radiotherapy.

6 have shifted towards fractionated conformal external beam radiotherapy.

7 ard treatment doses of both chemotherapy and external beam radiotherapy.

8 ing critical structures, and costs less than external beam radiotherapy.

9 greater than when delivered by fractionated external beam radiotherapy.

10 eceive or not receive postoperative adjuvant external-beam radiotherapy.

11 reatment for neuroblastoma than conventional external-beam radiotherapy.

12 patic toxicity similar to 40-Gy fractionated external-beam radiotherapy.

13 ter radical prostatectomy, brachytherapy, or external-beam radiotherapy.

14 adiotherapy, and three-dimensional conformal external-beam radiotherapy.

15 October 31, 1995, and treated initially with external-beam radiotherapy.

16 g of urinary obstruction and irritation with external beam radiotherapy (11.7 [95% CI, 8.7-14.8]) and

17 al prostatectomy (36.2 [95% CI, 30.4-42.0]), external beam radiotherapy (13.9 [95% CI, 6.7-21.2]), an

18 .5%), 469 radical prostatectomy (41.1%), 249 external beam radiotherapy (21.8%), and 109 brachytherap

19 5.1-25.9]); and worsened bowel symptoms with external beam radiotherapy (4.9 [95% CI, 2.4-7.4]).

20 operative radiotherapy, 37 [3.3%] of 1113 vs external beam radiotherapy, 44 [3.9%] of 1119; p=0.44).

21 an consisted of 5 weeks of concurrent pelvic external beam radiotherapy (45 Gy) with continuous intra

22 External beam radiotherapy (72.7%) was most commonly cho

23 All patients received external-beam radiotherapy according to a strict protoco

24 f 25 postprostatectomy patients who received external-beam radiotherapy after prostatectomy and who u

25 ent, including radical prostatectomy (RP) or external-beam radiotherapy alone, is associated with hig

26 ough there is evidence for tumor response to external beam radiotherapy and despite the fact that a r

27 ment strategies, namely surgery and adjuvant external beam radiotherapy and targeted intraoperative r

28 rcinoma of the esophagus received concurrent external-beam radiotherapy and chemotherapy followed by

29 on cavities (SCRCs) followed by conventional external-beam radiotherapy and chemotherapy.

30 rovide shorter, more convenient schedules of external-beam radiotherapy and interstitial treatment.

31 rom that of standard whole-breast tangential external-beam radiotherapy and necessitates investigatio

32 y of life (QOL) after radical prostatectomy, external beam radiotherapy, and brachytherapy vs active

33 ss of brachytherapy as comparable to that of external beam radiotherapy, and the side effect profile

34 oadjuvant chemotherapy, enucleation, orbital external-beam radiotherapy, and adjuvant chemotherapy.

35 than does standard-dose conventional radical external-beam radiotherapy, and could improve long-term

36 Utilization rates for prostatectomy, external-beam radiotherapy, and observation have fallen

37 Two patients also received external-beam radiotherapy before IAC.

38 were randomized to receive 70 Gy or 78 Gy of external-beam radiotherapy between 1993 and 1998.

39 ying QoL outcomes for radical prostatectomy, external beam radiotherapy, brachytherapy, and cryothera

40 Treatment with radical prostatectomy, external beam radiotherapy, brachytherapy, or active sur

41 reatment for almost a century, being used in external-beam radiotherapy, brachytherapy, and targeted

42 ry (radical prostatectomy) and radiotherapy (external-beam radiotherapy, brachytherapy, or both) are

43 rostatectomy, or three-dimensional conformal external-beam radiotherapy by a computer-generated alloc

44 External-beam radiotherapy continues to be an important

45 py should be considered as an alternative to external beam radiotherapy delivered over several weeks.

46 randomly assigned to receive 60 to 64 Gy of external beam radiotherapy delivered to the prostatic fo

47 Neither brachytherapy nor an increase in external beam radiotherapy dose has been proven to impro

48 antageous dose distribution than photons for external beam radiotherapy, due to their so-called inver

49 Radiation therapy (RT) including external beam radiotherapy (EBRT) and internal radioisot

50 ve radiotherapy (TARGIT) versus fractionated external beam radiotherapy (EBRT) for breast cancer.

51 eing compared with the standard fractionated external beam radiotherapy (EBRT) in randomized trials.

52 the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases

53 External beam radiotherapy (EBRT) was necessary in 33 ey

54 y was to determine in what manner aggressive external beam radiotherapy (EBRT), chemotherapy, surgica

55 Patients who underwent external beam radiotherapy (EBRT), radical prostatectomy

56 ndividuals with prostate cancer treated with external beam radiotherapy (EBRT).

57 y (100 microg/delivery) or hyperfractionated external beam radiotherapy (EBRT; 15 Gy total dose).

58 nt-free survival was defined as avoidance of external-beam radiotherapy (EBRT) and enucleation.

59 eprivation therapy (ADT) in combination with external-beam radiotherapy (EBRT) in men with locally ad

60 We evaluated the efficacy of external-beam radiotherapy (EBRT) in the palliation of p

61 idene diphosphonate (HEDP) as an adjuvant to external-beam radiotherapy (EBRT) in the treatment of pa

62 0; P = .01), low income (OR, 1.74; P < .01), external-beam radiotherapy (EBRT; OR, 0.85; P = .01), an

63 Patients then received conventional external-beam radiotherapy followed by a year of alkylat

64 s and technological advances in image-guided external beam radiotherapy for prostate cancer.

65 TRO) produced an evidence-based guideline on external-beam radiotherapy for patients with locally adv

66 Effects of external-beam radiotherapy for prostate cancer among a p

67 ts who develop an isolated PSA relapse after external-beam radiotherapy for prostate cancer.

68 ctive monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinical

69 rapy group (six patients [0.5%]) than in the external beam radiotherapy group (23 patients [2.1%]; p=

70 ve radiotherapy and 0.95% (0.39-2.31) in the external beam radiotherapy group (difference between gro

71 1025 (92%) patients in the external beam radiotherapy group received the allocated

72 operative radiotherapy group and five in the external beam radiotherapy group.

73 ancers, and combined anti-PD-L1 therapy with external beam radiotherapy has been shown to increase th

74 hemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatm

75 External beam radiotherapy has historically played a min

76 ormonal ablation therapy in combination with external-beam radiotherapy has shown improvement in prog

77 liable long-term results, and the studies of external-beam radiotherapy have used the best scientific

78 y arms administered before hyperfractionated external-beam radiotherapy (HFEBRT).

79 radiotherapy (3DCRT) and intensity-modulated external-beam radiotherapy (IMRT), better implant techni

80 omas may be safely managed with fractionated external beam radiotherapy in select patients with possi

81 The technique of external beam radiotherapy is most often used and is del

82 study indicates that although postoperative external-beam radiotherapy is highly effective in preven

83 ently, in metastatic disease, the utility of external-beam radiotherapy is limited.

84 = 8, 23%), plaque radiotherapy (n = 3, 9%), external beam radiotherapy (n = 1, 3%), cryotherapy (n =

85 External-beam radiotherapy of early prostate cancer is f

86 is recommended as a new standard of care for external-beam radiotherapy of localised prostate cancer.

87 risk groups for predicting the outcome after external-beam radiotherapy of localized prostate cancer.

88 rs in up to a third of patients treated with external beam radiotherapy or combined chemoradiotherapy

89 pressive tumor control, without the need for external beam radiotherapy or enucleation.

90 responses to venetoclax combined with either external beam radiotherapy or radioimmunotherapy (RIT),

91 otherapy, hormone therapy, immunotherapy, or external beam radiotherapy or those patients with a soli

92 ate cancer defined by Phoenix criteria after external-beam radiotherapy or brachytherapy as primary t

93 ty-seven and 41 patients had been treated by external-beam radiotherapy or brachytherapy, respectivel

94 erically equivalent to results achieved with external-beam radiotherapy or radical prostatectomy.

95 Standard treatment options include RP, external-beam radiotherapy, or hormonal ablation therapy

96 External-beam radiotherapy plays a critical role in the

97 We then assessed the efficacy of external beam radiotherapy plus venetoclax in murine xen

98 In each model, external beam radiotherapy plus venetoclax synergistical

99 treous chemotherapy have completely replaced external beam radiotherapy, reduced the use of systemic

100 e for 50% (BED50) of 115, 93, and 250 Gy for external-beam radiotherapy, resin microsphere radioembol

101 st in the role of local therapies, including external beam radiotherapy (RT), for men with metastatic

102 rogen deprivation (AD) after initial AD with external-beam radiotherapy (RT) in patients with locally

103 sociated with these treatments compared with external-beam radiotherapy (RT).(1,2).

104 In external-beam radiotherapy, these tumors present a chall

105 lobular carcinoma) could trigger addition of external beam radiotherapy to targeted intraoperative ra

106 Cryotherapy, plaque radiotherapy, external beam radiotherapy, tumor removal by partial lam

107 , bone metastasis, prior chemotherapy, prior external-beam radiotherapy, uptake on the [(111)In-DTPA(

108 Palliative external beam radiotherapy was administered.

109 f radiation oncologists believed surgery and external beam radiotherapy were equivalent treatments.

110 y one third of that produced by fractionated external beam radiotherapy, when measured by tumor regro

111 stration of tumor progression after standard external-beam radiotherapy with or without chemotherapy

112 intraoperative radiotherapy or whole breast external beam radiotherapy, with blocks stratified by ce

113 U) and cisplatin administered monthly before external-beam radiotherapy would improve the survival of

114 untreated (stratum A), newly diagnosed after external beam radiotherapy (XRT) (stratum B), and recurr

115 ere tested: (a) empty polymer (no drug); (b) external beam radiotherapy (XRT) alone; (c) local chemot